BioCeuticals Clinical NuroBalance Forte 60t

Description

Supports Healthy Mood Balance
NuroBalance Forte combines the latest in clinical research to provide patients with an effective mood support formula. Developed following emerging evidence in the areas of complementary medicine and mood, NuroBalance Forte features traditional and well-researched herbal ingredients.

• Combination of saffron and St John's wort, used in Persian traditional medicine and traditional western herbal medicine, respectively, to support a healthy mood balance, with mimosa, Siberian ginseng, zinc and myo-inositol.
• Contains affron®, a clinically trialled saffron extract shown to support healthy mood balance. affron® is standardised to contain at least 3.5% Lepticrosalides®, a measure of phyto compounds including the bioactive compounds safranal and crocin.
• Contains St John's wort extract standardised to hypericin and <1% hyperforin.
• Contains Siberian ginseng, used in traditional western herbal medicine as an adaptogen and to relieve fatigue, standardised to syringaresinol diglucosides.
• With the addition of: an extract equivalent to 1.5g of mimosa; zinc, to support cognitive function; and myo-inositol, which supports the signal transduction between nerve cells.

 

Each tablet contains:
Herbal extracts standardised equiv. to dry:
Hypericum perforatum (St John's wort) herb top flowering	2.7g
equiv. to hyperforin	13.5mg
equiv. to hypericins calc. as hypericin	1.49mg
Eleutherococcus senticosus (Siberian ginseng) root	2g
equiv. to syringaresinol diglucosides	1.06mg
Herbal extract equiv. to dry:
Albizia julibrissin (mimosa) stem bark outer	1.5g
Crocus sativus (saffron) stigma (affron®)	42mg
Nutrients:
Zinc amino acid chelate	62.5mg
equiv. to zinc	12.5mg
Inositol (myo-inositol)	300mg

 

No added dairy, gluten, shellfish, soy protein, yeast.
Vegan & vegetarian friendly.

St John's wort affects the way many prescription medicines work including the oral contraceptive pill; consult your doctor.

Prescribing Information:
Avoid using in pregnancy and lactation.
Concomitant use of St John's wort and drugs that elevate serotonin levels, such as tricyclic antidepressants or SSRIs, may result in additive or synergistic effects and increase the risk of serotonergic syndrome.
As the constituent hyperforin (in St John's wort) has a significant and selective induction effect on CYP3A4 and 2C19 activity, interactions are possible with those drugs that are substrates for CYP3A4 or 2C19 and/or rely on P-gp transport.
Breakthrough bleeding has been reported with use of St John's wort, which can indicate decreased effectiveness of oral contraceptives.
Saffron is not recommended in bipolar states.
Eleutherosides, particularly B and E, appear to inhibit the activity of CYP2C9 and CYP2E1 and may inhibit the metabolism of drugs metabolised by these pathways. Therefore, Siberian ginseng may falsely elevate assays for blood digoxin; increase the side effects of phenelzine and other MAOIs; increase the risk
of bleeding in patients taking warfarin; and increase tolerance for chemotherapy and improve immune response.
Since studies suggest that the effects of Siberian ginseng attenuate after four weeks of use, consideration of breaking treatment for two weeks after this period before resuming is clinically recommended in elderly patients with hypertension.